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Abstract
Background: Progressive neuron loss in the frontal and temporal lobes of the cerebral cortex typifies frontotemporal
lobar degeneration (FTLD). FTLD sub types are classified on the basis of neuronal aggregated protein deposits, typically
containing either aberrantly phosphorylated TDP-43 or tau. Our recent work demonstrated that tau tubulin kinases
1 and 2 (TTBK1/2) robustly phosphorylate TDP-43 and co-localize with phosphorylated TDP-43 in human postmortem
neurons from FTLD patients. Both TTBK1 and TTBK2 were initially identified as tau kinases and TTBK1 has been shown
to phosphorylate tau epitopes commonly observed in Alzheimer’s disease and other tauopathies.
Methods: To further elucidate how TTBK1/2 activity contributes to both TDP-43 and tau phosphorylation in the context
of the neurodegeneration seen in FTLD, we examined the consequences of elevated human TTBK1/2 kinase expression
in transgenic animal models of disease.
Results: We show that C. elegans co-expressing tau/TTBK1 tau/TTBK2, or TDP-43/TTBK1 transgenes in combination exhibit
synergistic exacerbation of behavioral abnormalities and increased pathological protein phosphorylation. We also
show that C. elegans co-expressing tau/TTBK1 or tau/TTBK2 transgenes in combination exhibit aberrant neuronal
architecture and neuron loss. Surprisingly, the TTBK2/TDP-43 transgenic combination showed no exacerbation of
TDP-43 proteinopathy related phenotypes. Additionally, we observed elevated TTBK1/2 protein expression in cortical and
hippocampal neurons of FTLD-tau and FTLD-TDP cases relative to normal controls.
Conclusions: Our findings suggest a possible etiology for the two most common FTLD subtypes through a kinase
activation driven mechanism of neurodegeneration.
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Background
Frontotemporal lobar degeneration (FTLD) is a progressive
neurodegenerative disease clinically diagnosed by evidence
of personality and behavioral changes and language dys-
function [1]. Following Alzheimer’s disease (AD), FTLD is
the second most prevalent form of presenile dementia af-
fecting 10-30 per 100,000 individuals between the ages of
45 and 65 years. In general, FTLD features atrophy of the
frontal and temporal lobes resulting from neuron loss [2].
FTLD is sub-classified into three major pathological
subtypes based on the presence of aggregated protein
deposits of either TDP-43 or tau inclusions, with a small
subset of cases exhibiting FUS-related pathology [2].
FTLD-TDP accounts for roughly 50% of cases whereas
FTLD-tau accounts for approximately 45% of cases [2].
FTLD-TDP presents with aberrantly processed, ubiquiti-
nated, and phosphorylated TDP-43 in neuronal inclusions
and dystrophic neurites. FTLD-tau, on the other hand, is
characterized by hyperphosphorylated aggregates of tau,
which form tangles and pick bodies in neurons, glia, and
neurites. Several mutations in MAPT reduce tau’s affinity
* Correspondence: kraemerb@u.washington.edu
1Geriatrics Research Education and Clinical Center, Veterans Affairs Puget
Sound Health Care System, S182, 1660 South Columbian Way, Seattle, WA
98108, USA
3Division of Gerontology and Geriatric Medicine, Department of Medicine,
University of Washington, Seattle, WA 98104, USA
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Taylor et al. Molecular Neurodegeneration  (2018) 13:7 
DOI 10.1186/s13024-018-0237-9
for microtubules and increase its aggregation rate and can
cause FTLD-tau [3].
Phosphorylation of TDP-43 at serine residues 409 and
410 remains a consistent pathological feature in ALS and
FTLD-TDP [4]. Phosphorylation of TDP-43 reduces TDP-
43 protein turnover, increases cellular mislocalization of
TDP-43, drives protein aggregation, and promotes neuro-
degeneration [5–9]. Likewise, hyperphosphorylated tau
protein is a hallmark of several neurodegenerative disor-
ders including AD, progressive supranuclear palsy (PSP),
corticobasal degeneration (CBD), and FTLD. Phosphory-
lated tau has been implicated in the formation of toxic tau
aggregates that promote neurodegeneration [10–15].
The kinases TTBK1 and TTBK2 have been implicated in
a number of neurodegenerative diseases. TTBK1 protein is
increased in AD and influences the aggregation of tau [16,
17]. Furthermore, transgenic mouse lines expressing full-
length human TTBK1 exhibit age-dependent detriments
consistent with neurodegeneration, including learning im-
pairment, neurofilament aggregation, microgliosis, altered
CDK5/p35 activity, and decreased expression of NMDA
receptors [18]. A double-transgenic mouse model express-
ing FTLD mutant tau and human TTBK1 shows increased
accumulation of oligomeric tau and enhanced motor
neuron loss, suggesting a direct role of TTBK1 in acceler-
ating tau-related neurodegeneration [19]. Mutations in
TTBK2 cause spinocerebellar ataxia type 11, a disorder
exhibiting both loss of Purkinje cells and widespread de-
position of tau [20]. TTBK2 plays an essential role in the
initiation of ciliogenesis during embryonic development
through the regulation of microtubule dynamics [21–23].
TTBK1 is solely expressed in the CNS and reproductive
tissues, whereas TTBK2 is ubiquitously expressed through-
out many tissues including liver, skeletal muscle, pancreas,
heart, and brain [24].
Purified recombinant human TTBK1 and TTBK2 can
directly phosphorylate both TDP-43 at S409/410 [9] and
tau at S198, S199, S202, and S422 [17] and S208 and 210
[25]. Additionally, both TTBK1 and TTBK2 co-localize
with phosphorylated TDP-43 (pTDP) in human postmor-
tem tissues from both FTLD and ALS cases [9] and phos-
phorylated tau (ptau) in AD cases [16]. Since TTBK1/2
phosphorylate both TDP-43 and tau, a common pathway
could be involved in the initiation of FTLD. While
TTBK1/2 directly phosphorylate TDP-43 and tau in vitro,
it remains unclear how TTBK1/2 activity in vivo influ-
ences disease onset and progression.
To examine how TTBK1/2 contribute to both TDP-43
and tau phosphorylation, we analyzed their effects on life-
span, proteostatic function, and neurodegeneration in the
context of tau or TDP-43 transgenic animal models. We
also examined the expression of TTBK1 and TTBK2 in
post-mortem human brain. We demonstrate that TTBK1/
2 kinase expression leads to significant neurodegenerative
phenotypes in our transgenic tau and TDP-43 models and
is also a consistent feature of FTLD-tau and FTLD-TDP.
Methods
C. elegans Strains
The N2 (Bristol) strain of C. elegans was used for all ex-
perimental controls and maintained as described [26].
Strains were maintained at 20 °C on OP50 seeded nema-
tode growth media (NGM). All experiments were
performed at room temperature unless otherwise desig-
nated. Construction and characterization of TDP-43
transgenic (tg) (CK410) and tau (high-expression)
(CK144) lines used were described previously [8]. Tau
(low-expression) (CK1044) tg strains were generated by
introducing wild type human full length 1N4R splice iso-
form tau cDNAs driven by the pan neuronal aex-3
promoter (Paex-3::Tau) into the C. elegans genome.
TTBK1 and TTBK2 kinase domain (hTTBK1-cat and
hTTBK2-cat) strains were constructed by introducing
human TTBK1 or TTBK2 cDNA encoding the kinase
domain, driven by the pan neuronal rgef-1 promoter
(Prgef-1::hTTBK1cat, Prgef-1::hTTBK2cat) (TTBK1:CK10
51; TTBK2:CK646, CK645) into the C. elegans genome.
Prgef-1::hTTBK1cat was microinjected into N2 at a con-
centration of 30 ng/μl with an elt-2::mCherry coinjection
marker at a concentration of 25 ng/μl. Prgef-1::hTTBK
2cat was microinjected into N2 at a concentration of
50 ng/μl with an elt-2::mCherry coinjection marker at a
concentration of 25 ng/μl. For all transgenic strains,
extrachromosomal arrays were then integrated by expos-
ing animals to a dose of 4000 Rad Gamma rays and sub-
sequently outcrossed back into the N2 background at
least twice. TTBK1 and TTBK2 strains used were CK10
51, CK645, CK646. Strain CZ1200 [27], which carries an
integrated Punc25::GFP transgene marker in GABAergic
motor neurons, was a generous gift from Dr. Y. Jin. CK1
051 and CK646 were crossed with CK1044, CK144, and
CK410 to generate homozygous double transgenic C.
elegans. CK646/CK1044 and CK1051/CK144 double
transgenic were subsequently crossed with CZ1200 to
produce triple transgenic lines with GFP marked GABA
ergic neurons.
Radial locomotion assay
Behavior was assessed by placing 15-20 age-matched
(L4) C. elegans at the center of a 150 mm NGM plate
supplemented with 5× peptone (5xPEP), with a uniform
OP50 bacterial lawn. After 1 h of free movement at
room temperature, the radial distance traveled from the
origin by each animal was measured. Distance from the
origin traveled per unit of time was expressed in micro-
meters per second to give a radial velocity. The assay was
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performed in triplicate by an observer blinded to genotype
and statistical analyses were performed using GraphPad
Prism software.
Lethality assay
CK144 was crossed with CK646 or CK645 and made
homozygous for either the tau or hTTBK2-cat transgene
to create the F1 population. From a single F1 parent,
each F2 progeny was isolated onto an individual plate
and the subsequent F3 offspring were scored for trans-
gene expression. Animals that did not survive past L2
were characterized as larval lethal. Animals that survived
into adulthood but did not produce progeny or died
prior to egg laying were classified as adult sterile. A chi-
squared analysis was performed to assess significance.
Neurodegeneration assays
Strains with Punc25::GFP-tagged (GABA)-ergic motor neu-
rons were generated by crossing to the reporter strain
CZ1200. Strains were staged to day 1 of adulthood and
immobilized on a 2% agarose pad with 0.01% sodium azide.
Live VD and DD GABAergic neurons were assessed under
fluorescent microscopy on DeltaVision Elite (Applied
Precision, Issaquah, WA) imaging system using an
Olympus 60× oil objective. The number of live neurons,
number of dorsal cord gaps, and percentage of neurons
with aberrantly branched neuronal commissures were
scored. Statistical significance was analyzed by perform-
ing a One-way ANOVA with a Tukey’s post-hoc test
using GraphPad Prism statistical software.
Lifespan analysis
C. elegans were synchronized to L4 stage from a timed
egg lay on NGM plates at 20 °C. Lifespan plates were
prepared from 30 mm NGM plates that were seeded
with 10X concentrated OP50 and treated with 10 mg/ml
5-fluorodeoxyuridine (FUDR). One hundred animals per
strain were assayed at 25 °C. Animals were checked daily
for signs of movement by observing locomotion and
pharyngeal pumping. Towards the end of life, animals
were tapped lightly with a platinum pick to look for a re-
sponse. Animals that failed to respond were counted as
dead and removed from the plate. Animals that died of
bursting, bagging, or mishandling were censored from
the data. Statistical significance was analyzed by per-
forming a Chi-squared analysis with a Mantel-Cox test
using GraphPad Prism software.
Immunoblotting
Mixed-stage populations of C. elegans were grown on
150 mm 5XPEP plates, washed with M9 buffer, and frozen
with liquid nitrogen. Protein lysates were prepared by son-
ication of frozen C. elegans pellets in lysis buffer (10 mM
Tris-HCL pH 7.5, 5 mM EDTA, 10% sucrose) at 70%
amplitude for 10 s, repeated three times. The lysate
was loaded and resolved on precast 4-15% gradient
SDS-PAGE gels (BioRad) and transferred to PVDF
membrane (Bio-Rad Immun-blot PVDF membrane) at
100 V for 32 m. Human TDP-43 was detected with the
commercially available monoclonal antibody ab57105
(Abcam, 1:2500) directed at human TDP-43 amino
acids 1-261. TDP-43 phosphorylated at S409/S410 was
detected by a commercially available monoclonal antibody
(Cosmobio, Catalog # TIP-PTD-M01, 1:1000). Total Tau
was detected with a pan-tau polyclonal antibody rb17025
(V. Lee lab, 1:3000) [28]. Tau phosphorylated at T181 was
detected by AT270 (Thermo Scientific; 1:15,000). Tau
phosphorylated at S202 was detected by CP13 (1:500), a
generous gift from Dr. Peter Davies (Albert Einstein
College of Medicine, Bronx, NY). Tau phosphorylated at
T231 was detected by AT180 (Thermo Scientific, 1:2000).
Tau phosphorylated at S396/404 was detected by PHF-1
(P. Davies lab, 1:2000) [29]. Load controls were detected
by probing for β-Tubulin as previously described [14].
Human post-mortem brain lysate was prepared by
homogenization of tissue in lysis buffer (50 mM HEPES
pH 7.5, 1 mM EDTA, 150 mM NaCl, 10% Glycerol, 0.1%
Triton X-100, 1 mM PMSF, 1 protease inhibitor pellet
(Roche cOmplete Mini)) followed with a 10 s sonication
at 50% amplitude using a Branson Sonifier with micro
tip. Total protein lysate was loaded in 5XSDS buffer (5%
SDS, 200 mM DTT, 50 mM Tris pH 6.8, 5 mM EDTA,
50% sucrose, 0.05% Bromophenol Blue) and resolved on
a precast 4-15% gradient SDS-PAGE gel (BioRad) at
200 V and transferred to PVDF membrane (Bio-Rad
Immun-blot PVDF membrane) at 100 V for 30 m. TTB
K1 was detected with the commercially available poly-
clonal antibody directed at N-terminal amino acids 240-
270 of human TTBK1 (Abcam, ab103944, 1:1000). TTB
K2 was detected with the commercially available anti-
body directed at the N-terminus (Abcam, ab67839).
Post-mortem human tissue
We obtained de-identified samples of postmortem tissue
from the University of Washington Alzheimer’s Disease
Research Center (ADRC) Neuropathology Core (PI, Dr.
C. Dirk Keene) after receiving human subjects approval
(University of Washington human subjects division
approval: HSD# 06-0492-E/A 01). FTLD cases were
selected on the basis of having an autopsy-confirmed
diagnosis of FTLD-tau or FTLD-TDP. Control samples
were from neurologically healthy control participants,
who were of a similar age and were confirmed to be
negative for neuropathologic changes of FTLD-tau or
FTLD-TDP using routine and immunohistochemical as-
says. Frontal cortex (prefrontal middle frontal gyrus) and
hippocampus (at the level of the lateral geniculate nu-
cleus) samples were dissected at the time of autopsy in
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coronally sliced brains fixed approximately 3 weeks in
10% neutral buffered formalin according to routine proto-
cols. Samples were processed and embedded in paraffin
according to standard protocols.
Immunohistochemistry and Immunofluorescence
Formalin-fixed, paraffin-embedded human brain tissue
samples were sectioned by the University of Washington
Alzheimer’s Disease Research Center neuropathology core
(Seattle, WA) onto standard charged glass microscope
slides. Primary antibodies used for immunohistochemistry
were anti-TTBK1 (Abcam, 1:100) and anti-TTBK2 (Abgent,
1:200). In order to minimize variability, sections from all
cases (normal and affected subjects) were stained simultan-
eously for each antibody. Briefly, 5 μm sections from the
frontal cortex and hippocampus were deparaffinized in xy-
lene, rehydrated through graded alcohols, and an antigen
retrieval step consisting of autoclaving sections in citrate
buffer (1.8 mM citric acid/ 8.2 mM sodium citrate) was per-
formed. Sections were treated for endogenous peroxidases
with 3% hydrogen peroxide, blocked in 5% milk, incubated
with primary antibody overnight at 4 °C, followed by bio-
tinylated secondary antibody for 45 min at room
temperature. Finally, sections were incubated in an avidin-
biotin complex (Vector’s Vectastain Elite ABC kit, Burlin-
game, CA) and the reaction product was visualized with
0.05% diaminobenzidine (DAB)/0.01% hydrogen peroxide
in PBS. Specificity of these antibodies has been previously
shown [9]. Immunohistochemistry photomicrographs were
taken with a digital camera and imported into Adobe
Photoshop for mounting. To optimize visualization of stain-
ing, photomicrographs were modified when necessary by
adjusting brightness and contrast.
For double label immunofluorescence experiments, sec-
tions were co-immunostained with TTBK1 or TTBK2 and
pathological tau as detected by pT231 specific monoclonal
antibody AT180 (ThermoScientific). AlexaFluor 647 goat
anti-mouse and 568 goat anti-rabbit secondary antibodies
(Molecular Probes) were used and autofluorescence was
quenched with 0.1% Sudan Black. Microscopy was per-
formed on a Delta Vision microscope (GE, Inc) using a 60×
or 100× oil immersion objective, a sCMOS camera, and
2 × 2 binning. Image analysis was performed using soft-
WoRx 6.0 Beta software (GE, Inc). Human brain samples
stained for AT180 and TTBK1 or TTBK2 were imaged on
a Leica TCS SP5 II confocal microscope using a 63× oil
immersion objective. Colocalization analysis of confocal im-
ages were conducted in ImageJ 1.51n using Coloc 2.
Results
Human TTBK1 and TTBK2 kinase domain transgenic C.
elegans are behaviorally normal
To understand whether TTBK1 and TTBK2 kinases play a
direct role in neurodegeneration, we constructed transgenic
(Tg) C. elegans lines expressing kinase catalytic do-
mains of human TTBK1 (hTTBK1-cat) or TTBK2 (hTT
BK2-cat) under the pan-neuronal promoter rgef-1 by
micro-injecting a plasmid transgene (Prgef-1::hTTBK1
and Pregef-1::hTTBK2). The resultant extrachromosomal
transgenic strains were exposed to gamma radiation to
create stable genomically integrated transgenic lines. Two
lines of each hTTBK1-cat and hTTBK2-cat were then
characterized for behavior using a radial locomotion assay.
We observed that both hTTBK1-cat lines exhibited hyper-
active locomotion when compared with wild type animals
(Additional file 1: Figure S1a). We hypothesize the motor
hyperactivity is a result of excess kinase activity. Neither
TTBK2-cat strain was significantly different from non-
transgenic C. elegans. One of each hTTBK1-cat and hTTB
K2-cat line was selected for further characterization and
used for the remainder of experiments. We measured the
lifespan of hTTBK1-cat, but saw no significant difference
in its median or maximum lifespan as compared to
wild-type C. elegans (Additional file 1: Figure S1b).
Similarly, TTBK2-cat had no significant changes in me-
dian or maximum lifespan as compared to wild-type
controls (Additional file 1: Figure S1c).
Co-expression of TTBK1 or TTBK2 with tau causes
behavioral abnormalities, aberrant phosphorylation,
and shortened lifespan
TTBK1 was originally characterized as a tau kinase and
shown to directly phosphorylate tau at Ser198, Ser199,
Ser202, and Ser422 in vitro [17]. To test whether TTBK1
driven phosphorylation of tau influences tauopathy
phenotypes, we crossed our hTTBK1-cat Tg line with
C. elegans strains expressing either low or high levels
of wild-type human tau (isoform 1N4R). High expression
tau Tg worms exhibit a variety of tau-dependent pheno-
types including impaired movement, age-dependent neu-
rodegeneration, and accumulation of detergent insoluble
phosphorylated tau [14]. The tau(high) Tg line expresses
approximately four-fold higher levels of tau than the tau(-
low) Tg line. Since the tau(high) worms already exhibit a
strong phenotype [14], we chose to assess phenotypic
changes in a tau(low) line. Tau(low) Tg C. elegans do not
display significant differences in locomotion as compared
to non-transgenic animals, whereas tau(high) Tg animals
do exhibit significant impairment. We observed a signifi-
cant reduction in locomotion velocity as measured by radial
dispersion in both hTTBK1-cat;tau(low) (70.7% reduc-
tion) and hTTBK1-cat;tau(high) (69.4% reduction) com-
pared to the respective tau transgenes alone (Fig. 1a-b).
We also observed a significant increase in both total
tau and phosphorylated tau at Thr181, Ser202, Thr231,
and Ser396/404 in hTTBK1-cat;tau(low) and hTTBK1-
cat;tau(high) strains (Fig. 1c-n). Furthermore, ablation
of the active site of the hTTBK1_mut transgene did not
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modify tau toxicity as measured by motor function
(Additional file 1: Figure S1d).
To assess whether TTBK2 catalytic activity could drive
tauopathy related phenotypes, we crossed hTTBK2-cat Tg
C. elegans lines with tau(low) and tau(high) Tg lines. We
asked whether TTBK2-cat activity could modulate tau-
induced behavioral defects and increase protein phosphor-
ylation. We found that hTTBK2-cat expression exacerbates
behavioral defects as indicated by a significant 50.6%
reduction in radial motor velocity in our tau(low) Tg lines
(Fig. 2a). Additionally, we saw a significant increase in
total tau and significant increases phosphorylated tau at
Thr181, Ser202, Thr231, and Ser396/404 (Fig. 2b-g).
Given the motor behavior and protein phosphorylation
phenotypes in our double transgenic hTTBK1-cat;tau and
hTTBK2-cat;tau C. elegans, we wanted to test whether
there was an effect on longevity. Tau worms lived to a
median age of 14 days post-development, whereas
a b
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Fig. 1 Expression of hTTBK1-cat causes neurodegenerative phenotypes in a tau background. a Staged hTTBK1-cat;tau transgenic L4 larvae exhibit
significantly decreased radial velocity relative to tau(low) and (b) tau(high) transgenic animals. Animals were measured for the linear distance traveled
from a central reference point over 1 h, N > 70 for each genotype. Significance was determined using an unpaired T-test. P < 0.0001 versus tau(low)
and P < 0.0001 versus tau(high). c hTTBK1-cat;tau(low) transgenic animals have increased total tau and ptau relative to tau(low) animals. Bar graphs
represent four independent replicate immunoblots of (d) Total tau, (e) pThr181, (f) pSer202, (g) pThr231, and (h) pSer396/404. Graphs are plotted in
relative intensity. Significance was determined using an unpaired T-test. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***). i hTTBK1-cat;tau(high) transgenic animals
have increased total tau and ptau relative to tau(high) animals. Bar graphs represent four independent replicate immunoblots of (j) Total tau, (k) pThr181,
(l) pSer202, (m) pThr231, and (n) pSer396/404. Graphs represent densitometry analysis and are plotted in relative intensity. Significance was determined
using an unpaired T-test. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***)
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hTTBK1-cat;tau worms lived to 12 days post-development
and hTTBK2-cat;tau worms lived to 11 days post-
development. This equates to a significant 14% reduction
in lifespan for hTTBK1-cat;tau and a significant 21% re-
duction in lifespan for hTTBK2-cat;tau transgenic animals
(Additional file 1: Figure S2a). These findings suggest the
tauopathy modification is strong enough to limit lifespan
as a consequence of synergy between TTBK1 or TTBK2
and tau.
Co-expression of high levels of tau and hTTBK2 causes
lethality
When crossing hTTBK2-cat with tau(high) Tg lines, we
were unable to obtain a homozygous hTTBK2-
cat;tau(high) population. To determine whether the two
transgenes were synthetic lethal in combination, we
counted the observed phenotypes of progeny in compari-
son to expected Mendelian ratios. We generated lines
homozygous for tau(high) and heterozygous for hTTBK2-
cat (tau(high)/tau(high); hTTBK2-cat/+). These animals
were allowed to self-fertilize and the resultant F2 progeny
were scored for the presence of a fluorescent co-injection
marker to infer the genotype of the F1 parent (hTTBK2-
cat/hTTBK2-cat, hTTBK2-cat/+, or +/+). Only 3.6%
(6/165) of progeny were homozygous for both tau and
TTBK2-cat, compared to the expected Mendelian
outcome of 25% for segregation of a single genetic trait in
the F1 generation (Table 1). Of those individual popula-
tions that were homozygous, 100% of subsequent progeny
a
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Fig. 2 Expression of hTTBK2-cat causes neurodegenerative phenotypes in a tau background. a Staged hTTBK2-cat;tau(low) transgenic L4 larvae
exhibit significantly decreased radial velocity relative to tau(low) and (b) tau(high) transgenic animals. Animals were measured for the linear distance traveled
from a central reference point over 1 h, n > 75 for each genotype. Significance was determined using an unpaired T-test. P < 0.0001. (b)
hTTBK2-cat;tau transgenic animals have increased total tau and ptau relative to tau animals. Bar graphs represent four independent replicate immunoblots
of (c) Total tau, (d) pThr181, (e) pSer202, (f) pThr231, and (g) pSer396/404. Graphs represent densitometry analysis and are plotted in relative
intensity. Significance was determined using an unpaired T-test. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***)
Table 1 Expression of TTBK2-cat is embryonic lethal in a high-
expression tau homozygous background
(Homozygous for TTBK2) Observed Expected
tau +/+ 6 (3.6%) 41 (25%)
tau +/− 30 (18.2%) 83 (50%)
tau −/− 50 (30.3%) 41 (25%)
Larval Dead 47 (28.5%) 0 (0%)
Adult Sterile 32 (19.4%) 0 (0%)
Total 165
(Homozygous for tau) Observed Expected
TTBK2 +/+ 18 (7.1%) 63.5 (25%)
TTBK2 +/− 99 (39.0%) 127 (50%)
TTBK2 −/− 61 (26.5%) 63.5 (25%)
Larval Dead 46 (18.1%) 0 (0%)
Adult Sterile 30 (11.8%) 0 (0%)
Total 254
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were dead as larvae. Additionally, we observed that 28.5%
(47/165) of F1s were dead as larvae and 19.4% (32/165) of
F1s that reached adulthood died prior to egg laying or
were sterile. To confirm the results, we repeated the ex-
periment with a second independent hTTBK2 line, and
made the parental genotype homozygous for hTTBK2-cat
and heterozygous for tau(high) (hTTBK2-cat/hTTBK2-cat;
tau(high)/+). Similar to our previous results, only 7.1%
(18/254) of F1 individuals were homozygous for both
hTTBK2-cat and tau(high) expression with 100% of subse-
quent F2 progeny observed dead as larvae. Additionally,
18.1% (46/254) of F1s were dead as larvae and of those
that developed to adulthood, 11.8% (30/254) were sterile
(Table 1). Based on these results, we conclude that TTBK2
kinase activity causes synthetic lethality when co-
expressed with high levels of human tau.
Co-expression of TTBK1 or TTBK2 with tau causes
neurodegeneration
To determine whether hTTBK1-cat;tau(high) and hTTB
K2-cat;tau(low) lines exhibit normal embryonic neuronal
development of GABAergic motor neurons, we crossed
our hTTBK1-cat;tau(high) and hTTBK2-cat;tau(low) trans-
genic animals to a strain carrying a fluorescent GABAergic
neuronal reporter driven by the glutamic acid decarboxyl-
ase (GAD) promoter (Punc25::GFP) [27]. Using this re-
porter, we can assess neuron loss and axonal integrity in
living animals with fluorescent microscopy. We scored
living GFP-tagged neurons in hTTBK1-cat;tau(high)
and hTTBK2-cat;tau(low) developing larvae. We found
that all transgenic C. elegans appear grossly develop-
mentally normal and all expected GABAergic neurons
were present and structurally sound at larval stage L1
(Additional file 1: Figure S3a-f). Additionally, we observed
that expression of hTTBK1-cat or hTTBK2-cat does not
affect GFP expression levels (Additional file 1: Figure S3g).
Previous evidence suggests phosphorylated tau is in-
creased in neurodegenerative diseases and correlates with
the formation of toxic tau aggregates [12, 13, 15]. We tested
whether TTBK1/2 driven increases in tau phosphorylation
cause neuron loss using the C. elegans strains described
above. In our hTTBK1-cat;tau(high) animals, we observed a
significant decrease in live GABAergic neurons in day 1
adult worms. Live hTTBK1-cat;tau(high) animals lost on
average 20% (3.8/19) of neurons as compared to 12.6%
(2.4/19) of neurons lost in tau animals by day one of adult-
hood (Fig. 3a and d). We also assessed whether neuronal
connectivity degenerates in these animals by counting gaps
in the continuity of the dorsal nerve cord. Whereas a non-
transgenic animal presents no degeneration of the nerve
cord in early adulthood, we found that hTTBK1-
cat;tau(high) animals had significant disruption of nerve
cord continuity with on average 7.0 dorsal cord gaps, as
compared to tau(high) alone with an average of 2.6
gaps (Fig. 3b and e). Lastly, in our double transgenic
hTTBK1-cat;tau(high) worms, there was strong evidence
for aberrant axonal branching. In non-transgenic animals,
healthy GABAergic motor neurons do not form
branches. To quantify this observation, we counted the
number of live neurons that exhibited abnormal branch-
ing. Our hTTBK1-cat;tau(high) line had on average 31% of
GABAergic motor neurons with aberrant branching
per worm as opposed to the tau worms, which only
had 10% of the same neurons displaying aberrant
branching (Fig. 3c and f ).
To investigate the role of TTBK2 in tau-mediated
neurodegeneration, we also assessed whether hTTBK2-
cat;tau(low) animals exhibited increased neuronal loss,
dorsal cord degeneration, and altered axonal architec-
ture. We found that in our hTTBK2-cat;tau(low) models
there was also a significant loss of GABAergic motor
neurons. The hTTBK2-cat;tau(low) animals had lost
on average 15% of their GABAergic neurons by day
one of adulthood while animals that expressed tau
alone lost on average 7% neurons. Furthermore, we
observed a significant increase in dorsal cord degen-
eration of our double transgenic line (2.3 gaps) in
comparison to those expressing tau alone (1.1 gaps)
as well as significantly more aberrant axonal branching in
our hTTBK2-cat;tau(low) lines (21%, 4 branched neurons)
versus the tau line (5%, 0.89 branched neurons) (Fig. 4a-f).
Together, these data suggest increased neurodegeneration
and neuronal dysfunction driven by TTBK1 and TTBK2
in tau transgenic C. elegans.
Co-expression of TTBK1, but not TTBK2 kinase domains
with TDP-43 causes behavioral abnormalities and
increased phosphorylated TDP-43
Given that human TTBK1 phosphorylates TDP-43 at S409/
410 in vitro and colocalizes with pathological TDP-43 in
both ALS and FTLD post-mortem tissues [9], we wanted to
observe the effects of TTBK1 activity on TDP-43 in vivo.
We crossed our hTTBK1-cat transgenic C. elegans to
hTDP-43 transgenic models expressing wild-type TDP-43
[8] to generate hTTBK1-cat;TDP-43 transgenic animals.
Animals expressing wild-type TDP-43 alone do not exhibit
motor defects as compared to non-transgenic animals. We
observed a significant decrease in hTTBK1;TDP-43 loco-
motion as measured by radial dispersion velocity relative to
TDP-43 alone (Fig. 5a). We then asked whether TTBK1
activity influenced accumulation or phosphorylation of
TDP-43. We found a significant increase in both total
TDP-43 and S409/410 phosphorylated TDP-43 (Fig. 5b-d)
in our double transgenic lines. Given the apparent effects
on pathological TDP-43 protein accumulation and the im-
pairment of motor phenotypes in our double transgenic
hTTBK1-cat;TDP-43 C. elegans, we wanted to test whether
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there was also an effect on longevity. However, we found
no significant difference in lifespan when compared to the
TDP-43 alone (Additional file 1: Figure S2b). Likewise,
hTTBK1_mut transgenes with a disrupted active site failed
to modify TDP-43 toxicity (Additional file 1: Figure S1d).
We also asked whether expression of hTTBK2-cat in
a TDP-43 background produces similar phenotypes by
crossing our hTTBK2-cat C. elegans line to wild-type
hTDP-43 transgenic C. elegans. Although there was a
slight increase in total TDP-43 and phosphorylated
TDP-43 levels, we did not observe a significant change
in behavior or phosphorylated TDP-43 accumulation in
the hTTBK2-cat;TDP-43 double transgenic (Additional
file 1: Figure S4), demonstrating that hTTBK2-cat likely
does not influence TDP-43 toxicity in vivo as strongly
as hTTBK1-cat.
TTBK1 levels are elevated in both FTLD-tau and FTLD-TDP
We have demonstrated in C. elegans that catalytically
active TTBK1 and TTBK2 promote tau and TDP-43 phos-
phorylation [9]. However, it is unknown whether there are
changes in the abundance of TTBK1 and TTBK2 in pa-
tients with FTLD. In order to assess whether elevation of
TTBK1 or TTBK2 occurs in FTLD, we examined TTBK1
and TTBK2 protein levels in human post-mortem brain
tissues of both FTLD-tau and FTLD-TDP patients. To
a
b
c
d e f
Fig. 3 Expression of hTTBK1-cat causes tau-dependent neuron loss and axonal abnormalities. GFP-labeled D-type GABAergic motor neurons were
observed in vivo in live day 1 adult transgenic C. elegans. a Fluorescent images of GABAergic live neurons in the posterior region. Each live
neuron is marked with an asterisk. b Fluorescent images of GABAergic dorsal cord. Gaps in dorsal cord are marked with brackets (c) Fluorescent images
of GABAergic axonal commissures. Aberrantly branched commissures are marked with arrows. d Number of neurons lost for each worm is
plotted. GFP-labeled controls lost an average of 0.22 neurons per animal (n = 22). hTTBK1-cat Tg animals lost an average of 0.06 neurons
(n = 46). Tau Tg animals lost an average of 2.4 neurons (n = 56). hTTBK1-cat;tau Tg animals lost an average of 3.8 Neurons (n = 49). P < 0.001 for tau versus
hTTBK1-cat;tau. e Number of dorsal cord gaps for each worm is plotted. hTTBK1-cat Tg animals had an average of 0.14 gaps (n = 21). Tau Tg animals had
an average of 2.6 gaps (n = 18). hTTBK1-cat;tau Tg animals had an average of 7.4 gaps (n = 10). P < 0.001 for tau versus hTTBK1-cat;tau (f)
Number of aberrantly branched commissures for each worm is plotted. hTTBK1-cat Tg animals had an average of 0 aberrantly branched neurons
(n = 20). Tau Tg animals had an average of 1.9 aberrantly branched neurons (n = 18). hTTBK1-cat;tau Tg animals had an average of 5.9 aberrantly branched
neurons (n = 20). P < 0.001 for tau versus TTBK1-cat;tau. Significance was determined using a one-way analysis of variance with Tukey’s
multiple comparison test among strains. Scale bar = 50 μm
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measure changes in protein abundance, we performed im-
munoblot analyses on human postmortem cortical tissue.
We found that in both FTLD-tau (n = 7) and FTLD-TDP
(n = 5) cases there was a visible increase in the levels of
proteolytically processed TTBK1 and TTBK2 kinase domain
bearing species as well as full length TTBK1 (Fig. 6a-d).
To establish the distribution of TTBK1/2 accumulation,
we examined TTBK1 and TTBK2 immunoreactivity in
the hippocampus and frontal cortex of FTLD-tau and
FTLD-TDP cases by immunohistochemistry. Our pre-
vious study demonstrated an increase in TTBK1 and
TTBK2 immunostaining in the frontal cortex of
FTLD-TDP cases [9]. In this study, we examined add-
itional FTLD-TDP cases and extended our analyses to
include the hippocampus. We again observed an in-
crease in TTBK1 and TTBK2 immunostaining in the
frontal cortex of FTLD-TDP cases relative to normal
controls (Figs. 7b and 8b). In contrast, immunoreactivity
in the hippocampus of FTLD-TDP cases was similar to
normal control cases (Figs. 7e and 8e). In FTLD-tau cases,
we observed increased TTBK1 and TTBK2 immunoreac-
tivity in both the frontal cortex and hippocampus relative
to normal controls (Fig. 7c and f; Fig. 8c and f). The in-
crease in TTBK1/2 immunostaining in the hippocampus
a
b
c
d e f
Fig. 4 Expression of hTTBK2-cat causes tau-dependent neuron loss and axonal abnormalities. GFP-labeled D-type GABAergic motor neurons were
observed in day 1 adult transgenic animals in vivo. a Fluorescent images of GABAergic live neurons in the posterior region. Each live neuron is
marked with an asterisk. b Fluorescent images of GABAergic dorsal cord. Gaps in dorsal cord are marked with brackets (c) Fluorescent images of
GABAergic axonal commissures. Aberrantly branched commissures are marked with arrows. d Number of neurons lost for each worm is
plotted. hTTBK2-cat Tg animals lost an average of 0.13 neurons (n = 23). Tau Tg animals lost an average of 1.4 neurons (n = 29). hTTBK2-cat;tau Tg animals
lost an average of 2.9 Neurons (n = 23). P < 0.001 for tau versus hTTBK2-cat;tau (e) Number of dorsal cord gaps for each worm is plotted. hTTBK2-cat Tg
animals had an average of 0.27 gaps (n = 22). Tau Tg animals had an average of 1.1 gaps (n = 28). hTTBK2-cat;tau Tg animals had an average of 2.3 gaps
(n = 20). P < 0.001 for tau versus hTTBK2-cat;tau (f) Number of aberrantly branched commissures for each worm is plotted. hTTBK2-cat Tg animals had an
average of 0.09 aberrantly branched neurons (n = 23). Tau Tg animals had an average of 0.9 aberrantly branched neurons (n = 29). hTTBK2-cat;tau Tg
animals had an average of 4.1 aberrantly branched neurons (n = 21). P < 0.001 for tau versus hTTBK2-cat;tau. Significance was determined
using a one-way analysis of variance with Tukey’s multiple comparison test among strains. Scale bar = 50 μm
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ab c d
Fig. 5 Expression of hTTBK1-cat causes neurodegenerative phenotypes in a TDP-43 background. a Staged hTTBK1-cat; TDP-43 transgenic L4 larvae
exhibit significantly decreased radial velocity relative to TDP-43 transgenic animals. Animals were measured for the linear distance traveled from a
central reference point over 1 h, N > 90 for each genotype. Significance was determined using an unpaired T-test. P < 0.01 versus TDP-43.
b hTTBK1-cat; TDP-43 transgenic animals have increased total TDP-43 and pTDP-43 relative to TDP-43 animals. Bar graphs represent six independent
replicate immunoblots of (c) Total TDP and (d) pTDP. Graphs are plotted in relative intensity. Significance was determined using an unpaired
T-test. P < 0.05 (*), P < 0.01 (**), P < 0.001 (***)
a b
c d
Fig. 6 FTLD cases exhibit increased levels of TTBK fragments. a Both FTLD-tau and FTLD-TDP patients exhibit significantly increased full-length TTBK1
and processed TTBK1 expression as compared to age-matched controls. b Bar graphs represent quantification of all TTBK1 bands present plotted in
relative intensity. Significance was determined using a one-way ANOVA. P < 0.001 (**). c Both FTLD-tau and FTLD-TDP patients exhibit significantly
increased processed TTBK2 kinase domain expression as compared to age-matched controls. d Bar graphs represent quantification of all TTBK2 bands
present plotted in relative intensity. Significance was determined using a one-way ANOVA
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d
g
e f
Fig. 7 FTLD cases exhibit increased TTBK1 immunostaining. Representative images demonstrating upregulation of TTBK1 immunoreactivity in FTLD brain
tissue (n = 5 cases of FTLD-TDP represented in panels b,e; n = 7 cases of FTLD-tau represented in panels (c, f)) compared to that of normal
control subjects (a, d). In the hippocampus (d-f), the increase in TTBK1 is highly robust in FTLD-tau cases relative to both FTLD-TDP cases and controls. In
the frontal cortex (a-c) there is enhanced TTBK1 immunoreactivity relative to normal controls, but the difference between the FTLD subtypes was less
apparent. Scale bar = 50 μm. g TTBK1 is expressed throughout the cytoplasm, and overlaps with phosphorylated tau (AT180) in human cells. Shown is
an image from a representative case (n = 3). Pearson coefficient of correlation for colocalization = 0.69 ± 0.18 for n = 46 neurons analyzed
a b c
d
g
e f
Fig. 8 FTLD cases exhibit increased TTBK2 immunostaining. Representative images demonstrating upregulation of TTBK2 immunoreactivity in FTLD brain
tissue (n = 5 cases of FTLD-TDP represented in panels b,e; 7 cases of FTLD-tau represented in panels (c, f) compared to that of normal control subjects
(a, d). In the hippocampus (d-f), the increase in TTBK2 is highly robust in FTLD-tau cases relative to both FTLD-TDP cases and controls. In the
frontal cortex (a-c) there is enhanced TTBK2 immunoreactivity relative to normal controls, but the difference between the FTLD subtypes was less
apparent. Scale bar = 50 μm. g TTBK2 is expressed throughout the cytoplasm, and overlaps with phosphorylated tau in human cells. Shown is
a representative case (n = 3). Pearson coefficient of correlation for colocalization = 0.57 ± 0.18 for n = 32 neurons analyzed
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of FTLD-tau cases is strikingly robust, especially in CA3
pyramidal neurons, and is more pronounced relative to
the increase observed in the frontal cortex of FTLD-TDP.
We previously showed that TTBK1 and TTBK2 co-
localize with phosphorylated TDP-43 in cytoplasmic
inclusions in FTLD-TDP cases. To determine whether
TTBK1/2 co-localize with phosphorylated tau in FTLD-
tau cases, we performed double label immunofluorescence
on hippocampal sections (Figs. 7g and 8g). We observed
TTBK1/2 immunofluorescence throughout the cytoplasm
of hippocampal pyramidal neurons that overlapped with
AT180 immunofluorescence in neurons positive for these
pathological tau deposits. In general, the co-localization of
TTBK1 with this phosphorylated tau species was stronger
than that of TTBK2. Taken together with our findings in
human brain tissue, this suggests that elevated levels of
TTBK1 and TTBK2 proteins are present in patients with
both FTLD-tau and FTLD-TDP and co-localize with
phosphorylated protein.
Discussion
Previous work has shown that TTBK1 and TTBK2 phos-
phorylate both tau [17, 25] and TDP-43 [30]. However, the
full extent to which tau and TDP-43 are phosphorylated by
TTBK1 and TTBK2 in vivo have yet to be described. It re-
mains unknown whether changes in TTBK1 and TTBK2
activity, abundance, and proteolytic processing influence
tau- and TDP-43-proteinopathies. To address these gaps in
knowledge, we generated transgenic C. elegans expressing
active human TTBK1 and TTBK2 kinase domains, and
evaluated their effects on tau and TDP-43 transgenic
models of FTLD. We also characterized TTBK1 and TTB
K2 expression patterns and levels in both FTLD-tau and
FTLD-TDP subtypes.
We found that hTTBK1-cat expression dramatically in-
creased total and phosphorylated protein levels of human
tau and TDP-43 in transgenic C. elegans resulting in exac-
erbated behavioral phenotypes and neurodegeneration.
Interestingly, while hTTBK2-cat expression drove accu-
mulation of total and phosphorylated tau and behavioral
defects in tau transgenic animals, hTTBK2-cat was rela-
tively neutral in TDP-43 transgenic animals. This suggests
an in vivo selectivity of TTBK1 and TTBK2 towards their
phosphorylation targets that differs from their in vitro
ability to phosphorylate purified TDP-43. Furthermore,
these data could also reflect regional or neuronal subtype
selectivity by TTBK2.
Although increases in TTBK1 expression have been pre-
viously shown in human AD cases [16], there have been no
studies examining changes in TTBK1 or TTBK2 abun-
dance in FTLD. In this study we show that both TTBK1
and TTBK2 protein levels increase as compared to age-
matched controls in FTLD-TDP and FTLD-tau cases.
These findings were seen in both immunoblot analyses and
immunohistochemistry studies. These results suggest that
changes in TTBK1 and TTBK2 abundance or processing
may influence their kinase activities towards tau and TDP-
43 in FTLD-tau and FTLD-TDP.
Importantly, this study suggests distinct target selectivity
between TTBK1 and TTBK2 kinase activity despite high
homology between the kinase domains (88% identity and
96% similarity) [24]. The differential regulation of TTBK1
vs TTBK2 activity is poorly understood. However, here
we show that TTBK2 kinase domain has a greater influ-
ence on promoting tau-induced neurodegeneration than
TTBK1, but it does not appear to affect TDP-43 in vivo.
Likewise, TTBK1 is able to phosphorylate both TDP-43
and tau in vivo, but appears to have a relatively modest
effect on tau compared to TTBK2. Investigations into the
regulation of TTBK1 and TTBK2 kinase activity and sub-
strate specificity are important next steps in determining
the roles of TTBK1 and TTBK2 in FTLD.
Conclusions
The identification of TTBK1 and TTBK2 as both tau and
TDP-43 kinases indicates a possible shared mechanism
for the initiation of TDP-43 proteinopathy and tauopathy
in FTLD. This is supported by the pathological presence
of either phosphorylated TDP-43 or tau in the majority of
FTLD cases, and the elevated protein expression of
TTBK1 and TTBK2 in both FTLD-tau and FTLD-TDP.
Therefore, the development of drugs to selectively inhibit
TTBK1 and TTBK2 may be a common therapeutic strat-
egy for both FTLD-tau and FTLD-TDP. In general, ki-
nases have become among one of the most important
classes of drug targets [31]. TTBK1 in particular makes an
attractive drug target due to its restricted expression in
neurons [24], unlike other tau kinases such as GSK3 and
CDK5 that are ubiquitously expressed [32, 33]. Further-
more, TTBK1 is one of the first kinases to be identified as
both a tau and TDP-43 kinase and our results suggest that
TTBK1 kinase activity is able to induce neurodegenerative
phenotypes in both tau and TDP-43 backgrounds. TTBK1
selective kinase inhibitors therefore represent a potential
means to treat both FTLD-tau and FTLD-TDP.
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